Table 1 Comparison of demographic and clinical features in the study groups.
Group L (N = 68) | Group M (N = 218) | Group H (N = 61) | F/χ2 | P | |
|---|---|---|---|---|---|
Demographics | |||||
Age (years) | 64.87 ± 10.41 | 65.52 ± 10.84 | 62.59 ± 8.19 | 1.927 | 0.147 |
Male, n (%) | 52 (76.47) | 179 (82.11) | 54 (88.52) | 3.184 | 0.204b |
Smoker, n (%) | 31 (45.59) | 128 (58.72) | 33 (54.10) | 3.659 | 0.160b |
Body-mass index (kg/m2) | 25.52 ± 3.83 | 25.03 ± 3.36 | 24.50 ± 4.09 | 1.287 | 0.277 |
Duration time (hours) | 52.85 ± 3.16 | 52.47 ± 3.67 | 52.32 ± 3.65 | 0.387 | 0.680 |
CYP2C19 gene | |||||
Slow, n (%) | 7 (10.29) | 18 (8.26) | 7 (11.48) | 5.596 | 0.231b |
Middle, n (%) | 30 (44.12) | 67 (30.73) | 20 (32.79) | ||
Rapid, n (%) | 31 (45.59) | 133 (61.01) | 34 (55.74) | ||
Medical history | |||||
Gastrointestinal bleeding, n (%) | 0 (0) | 6 (2.75) | 2 (3.28) | 1.922 | 0.349a |
Hematencephalon, n (%) | 0 (0) | 2 (0.92) | 0 (0) | 0.645 | 1.000a |
Hypertension, n (%) | 37 (55.41) | 124 (56.88) | 31 (50.82) | 0.737 | 0.692b |
Hyperlipidemia, n (%) | 22 (32.35) | 76 (34.86) | 24 (39.34) | 0.712 | 0.700b |
Diabetes mellitus, n (%) | 23 (33.82) | 71 (32.57) | 11 (18.03) | 5.281 | 0.071b |
Atrial fibrillation, n (%) | 47 (69.12) | 141 (64.68) | 49 (80.33) | 5.417 | 0.067 |
Fibrinolytic therapy, n (%) | 24 (35.29) | 51 (23.39) | 16 (26.23) | 3.794 | 0.150 |
ACS classification | |||||
STEMI, n (%) | 22 (32.35) | 61 (27.98) | 25 (40.98) | 3.818 | 0.148 |
NSTEMI, n (%) | 37 (54.41) | 95 (43.58) | 22 (36.07) | 4.537 | 0.103 |
UA, n (%) | 22 (32.35) | 53 (24.31) | 10 (16.39) | 4.439 | 0.109 |
Infarct-related artery | |||||
Left main coronary artery, n (%) | 10 (14.71) | 37 (16.97) | 4 (6.56) | 4.124 | 0.127 |
Anterior descending, n (%) | 40 (58.82) | 126 (57.80) | 31 (50.82) | 2.098 | 0.925a |
Circumflex artery, n (%) | 9 (13.24) | 30 (13.76) | 6 (9.84) | 2.031 | 0.732 a |
Right coronary artery, n (%) | 23 (33.82) | 64 (29.36) | 16 (26.23) | 7.045 | 0.491a |
Drug information | |||||
Dual antiplatelet (aspirin + clopidogrel), n (%) | 65 (95.59) | 206 (94.50) | 57 (93.44) | 0.287 | 0.866b |
Oral anticoagulant, n (%) | 47 (69.12) | 141 (64.68) | 49 (80.33) | 5.417 | 0.067 |
Statin, n (%) | 67 (98.53) | 216 (99.08) | 60 (98.36) | 1.008 | 0.630a |
ACEI/ARB, n (%) | 54 (79.41) | 170 (77.98) | 52 (85.25) | 1.546 | 0.462b |
β-blocker, n (%) | 62 (91.18) | 191 (87.61) | 54 (88.52) | 0.645 | 0.724b |
MACE, n (%) | 1 (1.47) | 1 (0.46) | 0 (0) | 1.580 | 0.606a |
